NATICK, Mass.--(BUSINESS WIRE)--Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, today announced a $33.4 ...
WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the launch of the DART 2.0 prospective clinical trial (NCT05541016) by Mayo Clinic.
CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Brisbane biotech company underwent five restructurings and faced a nearly $100 million patent judgment before its new CEO ...
CareDx has agreed to acquire Naveris in a deal worth up to $260m, priming the company to inherit a blood‑based monitoring solution for viral‑mediated cancers. CareDx's deal for the precision oncology ...
Life sciences company Naveris has raised $33.4 million in an expansion of its series A financing round. The recent funding round brings Naveris’ total capital raised to $51 million. The financing will ...
Caredx Inc. has agreed to acquire Naveris Inc., a precision oncology diagnostics company, for up to $260 million, as part of its strategy to accelerate growth. The acquisition comes as Caredx, an ...
BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results